Background: In the absence of liver biopsy, the World Health Organization recom-
| INTRODUCTION
Hepatitis B virus (HBV) infection is a major global health problem, despite the availability of effective vaccine prophylaxis. It is estimated that one-third of the world's population have been infected with HBV at some point in their lives, of whom 240 million people are chronically infected. Approximately 15%-25% of adults who were infected with HBV in childhood go on to develop its main complications, cirrhosis and/or hepatocellular carcinoma (HCC), and an estimated 686 000 deaths each year can be attributed to chronic hepatitis B (CHB).
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International liver societies have issued guidelines for the treatment of CHB, [4] [5] [6] but the optimal timing of treatment is still debated.
In general, treatment is recommended to persons with CHB who have high viral replication and moderate to severe liver inflammation and/ or fibrosis, as these patients are at high risk of disease progression to cirrhosis and HCC. 7, 8 The benefit of treatment for those with mild inflammation or fibrosis is less certain. Since the risk of complications increases dramatically once cirrhosis develops, it is of particular importance to detect patients with early cirrhosis.
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Assessment of liver fibrosis is a major challenge in the management of patients with CHB. Liver biopsy has traditionally been considered the gold standard; however, it is an invasive procedure with certain risks and limitations, and lack of trained personnel restricts its use in low-and middle-income countries. Africa. [24] [25] [26] Indeed, in the largest of the three, the performance of APRI and FIB-4 was only moderate compared to liver biopsy, although a novel fibrosis marker, GPR (gamma-glutamyl transpeptidase [GGT] to platelet ratio) appeared to perform better in this setting.
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The WHO has recognised the lack of evidence for the use of NITs in sub-Saharan Africa, and has called for further validation studies in African CHB patients. 22 In the present study, we assessed the performance of APRI, FIB-4 and GPR in one of the largest CHB cohorts in sub-Saharan Africa, aiming to provide local data and guide evidencebased practice on the continent.
| MATERIALS AND METHODS

| Study setting and participants
Ethiopia is a low-income country located in the eastern part of Africa with a high to intermediate prevalence of CHB. Based on different institution based studies, the prevalence of HBsAg has been estimated to be around 8%-12%, with a higher prevalence in cities. 
| Laboratory analyses
HBV infection was confirmed with a WHO validated HBsAg rapid test kit (Determine, Alere, Ireland) at enrolment, and HBsAg positivity for at least 6 months was the diagnostic criteria for CHB. All patients
Key points
• The World Health Organization recommends non-invasive tests to assess liver fibrosis in patients with chronic hepatitis B, but these tests are not validated in sub-Saharan Africa.
• We compared the performance of APRI, FIB-4 and the novel marker GPR with Fibroscan in a large hepatitis B cohort in Ethiopia.
• Although the area under the receiver operating characteristics curve (AUROC) was high for all tests, the sensitivity to detect patients in need of antiviral therapy was poor.
• Our study supports the use of these simple and affordable tests in sub-Saharan Africa, but suggests that decision thresholds might need modification in this setting. The median of 10 readings was employed, and the result was discarded if the interquartile range (IQR) divided by the median exceeded 30%.
| Statistical analysis
Based on a previous meta-analysis, we used a Fibroscan threshold of 7.9 kPa to define significant fibrosis (Metavir score ≥F2) and 11.7 kPa to define cirrhosis (Metavir score F4). 
| RESULTS
| Patient characteristics
| Performance of non-invasive tests
The different non-invasive markers of liver fibrosis were compared with transient elastography. Table 2 .
The sensitivities of the conventional NITs were low, both to detect fibrosis and cirrhosis. For APRI the higher threshold yielded a sensitivity of merely 10%, although the specificity was high at nearly 100%.
GPR had a better performance with a sensitivity of 36% and a specificity of 98% using the higher threshold.
T A B L E 1 Baseline characteristics of 582 Ethiopian patients with chronic hepatitis B
Characteristics
Median (IQR)
Age (years) 31 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) Fasting TE value (kPa) 5.8 (4.6-7.7)
Platelet count (10 
| DISCUSSION
In this study both APRI, FIB-4 and GPR had a high AUROC to detect significant fibrosis and cirrhosis in Ethiopian CHB patients. Our results were slightly better than those found in a recent meta-analysis of studies from Europe, Australia and Asia, where the summary AUROC of APRI was 0.74 for fibrosis and 0.73 for cirrhosis, and the summary AUROC for FIB-4 was 0.78 for fibrosis and 0.82 for cirrhosis.
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F I G U R E 1 Box plots of (A) GPR, (B) APRI, and (C) FIB-4 compared to the degree of fibrosis in a cohort of patients with chronic hepatitis B in Ethiopia. Fibroscan categories were: normal (≤7.9 kPa), fibrosis (8.0-11.7 kPa), cirrhosis (>11.7 kPa)
F I G U R E 2 Receiver operating curves for APRI, FIB-4 and GPR to detect (A) significant fibrosis (Fibroscan >7.9 kPa) and (B) cirrhosis (Fibroscan >11.7 kPa) in patients with chronic hepatitis B in Ethiopia
The performance of APRI and FIB-4 in studies from CHB patients in sub-Saharan Africa has been less favourable. In a study from Burkina Faso the AUROC of APRI to predict significant fibrosis and cirrhosis was 0.61 and 0.50, respectively, the latter being identical to chance.
FIB-4 had a better performance, the AUROC was 0.71 for fibrosis and 0.74 for cirrhosis. 25 In a study from the Gambia and Senegal the performance of NITs was also inferior to the findings in our study:
the AUROC of APRI was 0.62-0.66 for fibrosis and 0.70 for cirrhosis, whereas the AUROC for FIB-4 was 0.57-0.66 for fibrosis and 0.73 for cirrhosis, respectively. 24 Although our results suggest that APRI and FIB-4 have good diagnostic properties in African CHB monoinfected patients, further studies from the continent are needed before strong conclusions can be drawn.
In spite of the high AUROC for APRI and FIB-4 in our study, the sensitivity using existing thresholds was poor. Indeed, APRI detected only 10% of patients with significant fibrosis or cirrhosis using the higher thresholds recommended by the WHO. In clinical practice, this means that 90% of patients with cirrhosis will be erroneously labelled as non-cirrhotic and not receive appropriate treatment and follow-up.
Similarly, 90% of patients with significant fibrosis, who should commence treatment in order to avoid progressive liver disease, will pass unnoticed using the recommended APRI threshold. A similar trend was observed in the study by Lemoine et al. from West Africa: APRI had a sensitivity of 0% to detect significant fibrosis in Senegal, whereas the sensitivity was 9% to detect significant fibrosis and 25% to detect cirrhosis in Gambia. 24 Taken together with our findings, these data suggest that established thresholds, mainly derived from European and Asian patient cohorts, might need modification when employed in Africa.
The new fibrosis marker GPR was better than APRI and FIB-4 in the study by Lemoine et al. 24 However, since only patients with suspected advanced liver disease were included in the study, the results might not be representative of all patients with chronic HBV infection.
Furthermore, the study was carried out in a predominantly Muslim community where alcohol consumption, which might affect GGT levels, is lower than in many other areas in Africa. In our study the AUROC of GPR was not significantly better than the traditional markers; however, GPR had a more favourable sensitivity: 45% for significant fibrosis and 36% for cirrhosis.
The GPR has not been assessed in other African CHB monoinfected patient cohorts, but a few studies have been published from other parts of the world. In a recent study from China the AUROC of GPR to predict significant fibrosis (0.72) was significantly lower than APRI (0.78) and comparable to FIB-4 (0.70). To predict cirrhosis, the AUROC of GPR (0.78) was also inferior to APRI (0.83) and similar to FIB-4 (0.75). 35 Furthermore, in a recent small study from Brazil, there T A B L E 2 Diagnostic performance of non-invasive markers to detect significant fibrosis (Fibroscan >7.9 kPa) and cirrhosis (Fibroscan >11.7 kPa) in Ethiopian patients with chronic hepatitis B APRI, aspartate aminotransferase to platelet ratio index; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; GPR, gamma-glutamyl transpeptidase to platelet ratio; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
